双生物标志物模型可预测危重脓毒症患者的死亡风险
该研究从学术医疗中心ICU前瞻性纳入符合4条SIRS标准中2条的危重患者,获取血浆检测8种生物标志物,建立并验证了预测28天死亡的双生物标志物模型。推导队列(n=888)AUC为0.79(95%CI 0.74-0.83),内部测试队列(n=278)AUC为0.75(95%CI 0.65-0.85),外部验证队列(n=759)AUC为0.77(95%CI 0.72-0.83)。模型评分阈值对死亡的阴性预测值为0.95,低于阈值者ICU住院时间更短,急性肾损伤、急性呼吸窘迫综合征和需要血管升压药的发生率更低。该模型有助于在ICU床旁识别SIRS/脓毒症低风险患者。
要点
- 在符合2条SIRS标准的危重患者中,双生物标志物模型预测28天死亡的推导队列AUC为0.79(95%CI 0.74-0.83)。
- 模型在内部测试队列AUC为0.75(95%CI 0.65-0.85),外部验证队列AUC为0.77(95%CI 0.72-0.83)。
- 模型评分低于某阈值时,对死亡的阴性预测值为0.95。
- 低于该阈值的患者ICU住院时间更短,急性肾损伤、急性呼吸窘迫综合征和需要血管升压药的发生率更低。
- 该模型仅基于血浆生物标志物,用于SIRS/脓毒症患者死亡和器官功能障碍的风险分层。
适用人群与场景
- 推导队列和内部测试队列来自学术医疗中心ICU的前瞻性研究,纳入符合4条SIRS标准中2条、并在24小时内获取血浆的危重患者。
- 外部验证队列来自另一学术医疗中心ICU的前瞻性队列,纳入在48小时内获取血浆的危重患者。
诊断标准与关键阈值
- SIRS标准:符合4条SIRS标准中的2条。
- 模型评分阈值:原文报告该阈值对死亡的阴性预测值为0.95,未给出具体界值。
研究设计与关键结果
- 研究类型:前瞻性队列研究,建立并验证双生物标志物模型;推导队列n=888,内部测试队列n=278,外部验证队列n=759。
- 检测的生物标志物包括:血管生成素-1、血管生成素-2、IL-6、IL-8、可溶性肿瘤坏死因子受体-1、可溶性血管细胞黏附分子-1、粒细胞集落刺激因子和可溶性Fas。
- 推导队列中双生物标志物模型预测28天死亡的AUC为0.79(95%CI 0.74-0.83)。
- 内部测试队列AUC为0.75(95%CI 0.65-0.85),外部验证队列AUC为0.77(95%CI 0.72-0.83)。
- 模型评分阈值对死亡的阴性预测值为0.95。
- 低于阈值的患者ICU住院时间更短,急性肾损伤、急性呼吸窘迫综合征和需要血管升压药的发生率更低。
证据类型、等级与局限
- 证据类型:前瞻性队列研究(推导、内部测试和外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU中符合2条SIRS标准的危重患者,该双生物标志物模型可帮助识别28天死亡和器官功能障碍低风险者;评分低于阈值者死亡阴性预测值为0.95,且ICU住院时间更短、急性肾损伤、急性呼吸窘迫综合征和需要血管升压药的发生率更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Improving the prospective identification of patients with systemic inflammatory response syndrome (SIRS) and sepsis at low risk for organ dysfunction and death is a major clinical challenge.
OBJECTIVES: To develop and validate a multibiomarker-based prediction model for 28-day mortality in critically ill patients with SIRS and sepsis.
METHODS: A derivation cohort (n = 888) and internal test cohort (n = 278) were taken from a prospective study of critically ill intensive care unit (ICU) patients meeting two of four SIRS criteria at an academic medical center for whom plasma was obtained within 24 hours. The validation cohort (n = 759) was taken from a prospective cohort enrolled at another academic medical center ICU for whom plasma was obtained within 48 hours. We measured concentrations of angiopoietin-1, angiopoietin-2, IL-6, IL-8, soluble tumor necrosis factor receptor-1, soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.
MEASUREMENTS AND MAIN RESULTS: We identified a two-biomarker model in the derivation cohort that predicted mortality (area under the receiver operator characteristic curve [AUC], 0.79; 95% confidence interval [CI], 0.74-0.83). It performed well in the internal test cohort (AUC, 0.75; 95% CI, 0.65-0.85) and the external validation cohort (AUC, 0.77; 95% CI, 0.72-0.83). We determined a model score threshold demonstrating high negative predictive value (0.95) for death. In addition to a low risk of death, patients below this threshold had shorter ICU length of stay, lower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopressors.
CONCLUSIONS: We have developed a simple, robust biomarker-based model that identifies patients with SIRS/sepsis at low risk for death and organ dysfunction.
参考来源
- Mikacenic C, Price BL, Harju-Baker S, et al. A Two-Biomarker Model Predicts Mortality in the Critically Ill with Sepsis. Am J Respir Crit Care Med. 2017. PMID: 28418697. doi:10.1164/rccm.201611-2307OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。